• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ypsomed, Mediq complete sale of DiaExpert

January 3, 2023 By Sean Whooley

Ypsomed Logo 770x500Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert.

Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies.

That focus continues to narrow after last month’s announcement of the discontinuation of Ypsomed’s agreement with Eli Lilly. Lilly elected to stop their joint collaboration to enter the U.S. insulin pump market.

Burgdorf, Switzerland-based Ypsomed’s technologies include the YpsoPump insulin pump. The company recently announced German authorization for the use of its pump with Abbott and CamDiab’s technologies, forming an automated insulin delivery system.

Ypsomed said it obtained all approvals and fulfilled all conditions for the transaction by the end of 2022. Today’s announcement confirms the legal completion of the deal, leading to a heightened focus on the company’s own products.

“In the area of injection systems and in our insulin pump business, we see enormous growth potential in the coming years. Digitization also offers new business models and opportunities,” said Ypsomed CEO Simon Michel. “We are therefore continuing on our path to becoming a provider of integrated healthcare services.”

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Technology Tagged With: Ypsomed

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS